A route to market through a shell
Rather than a traditional initial public offering, Ellipses has chosen to go through Wolfram Resources, a London-listed special purpose acquisition company. The key points of the deal:
- A listing via reverse takeover by shell company Wolfram Resources; terms have yet to be agreed and have not been disclosed.
- Completion targeted for early 2027, together with an equity fundraise.
- A target valuation of £450 million to £500 million, according to The Times.
Founder and chair Chris Evans said listing through a reverse takeover would enable the company to raise additional capital from public company investors.
A different model of drug development
Chris Evans is a scientist-entrepreneur in his fourth decade in the industry who has been involved in the creation and growth of more than 50 companies. Ellipses seeks out promising drugs, develops them through clinical trials with uninterrupted funding, and then licenses them out.

















